基本情況：
2003网站太阳集团，2003网站太阳集团，副教授，博士生導師。2011年于華南師範大學獲得生物物理學博士學位，并于同年赴美國紐約大學醫學院細胞生物學系進行博士後研究。2013年起在明尼蘇達大學荷美爾醫學研究所任荷美爾研究員，2015年受聘于2003网站太阳集团生物學院&2003网站太阳集团，現為副教授，博士生導師。主要研究方向為腫瘤遺傳的分子機制及靶向治療新方法的探索，近年來一直關注于細胞死亡、自噬和免疫的關系，及其在腫瘤治療中的應用。作為獨立PI開展工作以來，詳細闡述了突變體p53促進結直腸癌發生發展的獲得性功能（GOF）及産生抗藥性的機理，同時鑒定出兩種全新的結直腸癌生物标志物PUMA和SIRT6。主持國家自然科學基金1項，湖南省重大研發計劃子課題1項，湖南省自然科學基金1項，深圳市科創委基礎研究項目1項。以通訊作者在Inter. J. Bio. Sci, Theranostics, Materials Today Bio, Cell Death & Dis等多個著名國際期刊上發表論文17篇，他引總次數超過1000。主講課程《細胞工程》入選湖南省一流本科課程，榮獲2019年湖南省高校教師課堂教學競賽二等獎，2018年2003网站太阳集团講課比賽一等獎。Tel：18673177768；E-mail：yingjiezhang@hnu.edu.cn
教育和培訓經曆：
2006-2011 華南師範大學生物光子學研究院，生物物理專業，博士
2011-2013 紐約大學醫學院，細胞生物學系，博士後
工作經曆：
2013-2015 明尼蘇達大學，荷美爾醫學研究所
2015-至今 2003网站太阳集团，生物學院&2003网站太阳集团
學術兼職：
中國抗癌協會會員
中國遺傳學會會員
中國生物化學學會會員
研究領域：
1. 腫瘤遺傳，免疫及轉化醫學；
2. 細胞死亡自噬及免疫的分子機制和信号轉導通路；
3. 鑒定新的腫瘤生物标志物，治療靶點并進行藥物篩選；
4. 利用新型納米/高分子材料進行腫瘤的原位靶向治療。
主持項目：
1. 湖南省重大研發計劃子課題，2020DK2001，高穩定性轉基因小鼠腫瘤模型構建的關鍵技術研發，2020/01-2022/12，10萬元，在研，主持
2. 湖南省自然科學基金面上項目，2020JJ4182，突變體p53的獲得性功能及其在淋巴瘤中的應用研究，2020/01-2022/12，5萬元，在研，主持
3. 國家自然科學基金青年項目，31801140，PUMA調控自噬的分子機制及其在結直腸癌中的功能研究，2019/01-2021/12，26萬元，在研，主持
4. 深圳市科創委基礎研究項目，JCYJ20160530192802733，PUMA在腫瘤自噬中的功能和分子機制研究，2017/03-2019/02，30萬元，已結題，主持
5. 中央高校基礎科研項目，531107040909，靶向Akt治療結直腸癌分子機制的研究，2015/09-2019/08，20萬元，已結題，主持
發表論文：
1. Nannan Liu, Xinxiu Jiang, Leiming Guo, Chuchu Zhang, Meimei Jiang, Zhuoran Sun, Yizheng Zhang, Wunan Mi, Jiehan Li, Yang Fu, Feng Wang, Lingling Zhang* and Yingjie Zhang*. “Mutant p53 achieved Gain-of-Function by promoting tumor growth and immune escape through PHLPP2/AKT/PD-L1 pathway”. International Journal of Biological Sciences 2022; 18(6): 2419-2438. doi: 10.7150/ijbs.67200. (IF: 10.75)
2. Jiehan Li, Guang Luo, Chuchu Zhang, Shuaiyu Long, Leiming Guo, Ge Yang, Feng Wang, Lingling Zhang, Liyang Shi*, Yang Fu* and Yingjie Zhang*. “In situ Injectable Hydrogel-loaded Drugs Induce Anti-tumor Immune Responses in Melanoma Immunochemotherapy”. Materials Today Bio 2022; doi:10.1016/j.mtbio.2022.100238. (IF: 10.761)
3. Yizheng Zhang,Chuchu Zhang,Jiehan Li,Meimei Jiang,Shuning Guo,Ge Yang,Lingling Zhang*,Feng Wang,Shiqi Yi,Jiangang Wang,Yang Fu*, Yingjie Zhang*.“Inhibition of AKT induce p53/SIRT6/PARP1-dependent parthanatos to suppress tumor growth”. Cell Communication and Signaling 2022; Doi:10.1186/s12964-022-00897-1. (IF: 7.525)
4. Tingting Hu, Yingjie Zhang, Tianqing Yang, Qingnan He, Mingyi Zhao. “LYPD3, a New Biomarker and Therapeutic Target for Acute Myelogenous Leukemia”. Frontiers in Genetics 2022; doi: 10.3389/fgene.2022.795820. eCollection 2022. (IF: 4.772)
5. Wunan Mi, Chuyue Wang, Guang Luo, Jiehan Li, Yizheng Zhang, Meimei Jiang, Chuchu Zhang, Nannan Liu, Xinxiu Jiang, Ge Yang, Lingling Zhang, Ge Zhang, Yang Fu*, Yingjie Zhang*, Yang Fu*. “Targeting ERK induced cell death and p53/ROS-dependent protective autophagy in colorectal cancer”. Cell Death Discovery. 2021; 7: 375. doi: 10.1038/s41420-021-00677-9. (IF: 7.109)
6. Huanan Wang, Yeying Liu, Jie Ding, Yuan Huang, Jing Liu, Nannan Liu, Yue Ao, Yi Hong, Lefeng Wang, Lingling Zhang, Jiangang Wang and Yingjie Zhang*. “Targeting mTOR suppressed colon cancer growth through 4EBP1/eIF-4E/PUMA pathway”. Cancer Gene Therapy 2020; doi: 10.1038/s41417-019-0117-7. (IF: 5.854)
7. Jing Liu, Shuaiyu Long, Huanan Wang, Nannan Liu, Chuchu Zhang, Lingling Zhang and Yingjie Zhang*. “Blocking AMPK/ULK1‑dependent autophagy promoted apoptosis and suppressed colon cancer growth”. Cancer Cell International 2019; 19: 336. doi: 10.1186/s12935-019-1054-0. (IF: 6.429)
8. Yuan Huang, Nannan Liu, Jing Liu, Yeying Liu, Chuchu Zhang, Shuaiyu Long, Guang Luo, Lingling Zhang and Yingjie Zhang*. “Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA”. Cell Cycle 2019; 14: 1-14. (IF: 5.173)
9. Yeying Liu, Yuan Huang, Jie Ding, Nannan Liu, Shuang Peng, Jiangang Wang, Feng Wang and Yingjie Zhang*. “Targeting Akt by SC66 triggers GSK-3β mediated apoptosis in colon cancer therapy”. Cancer Cell International 2019; 9(19): 124. (IF: 6.429)
10. Yingjie Zhang, Liming Nie, Keqian Xu, Yang Fu, Juchang Zhong, Kongzhen, Gu, Lingling Zhang. “SIRT6, A Novel Direct Transcriptional Target of FoxO3a, Mediates Colon Cancer Therapy”. Theranostics 2019; 9(8) 2380-2394. (IF: 11.6)
11. Jingfei Chen, Juchang Zhong, Yeying Liu, Yuan Huang, Fei Luo, Yingjun Zhou, Xi Pan, Shousong, Cao, Lingling Zhang, Yingjie Zhang*, Jiangang Wang*. “Purified vitexin compound 1, a new neolignan isolated compound, promotes PUMA-dependent apoptosis in colorectal cancer”. Cancer Medicine 2018; 7(12): 6158-6169. (IF: 4.711)
12. Juchang Zhong#, Yingjie Zhang#, Jingfei Chen, Ruiying Huang, Yikun Yang, Haoxiang Chen, Yuan Huang, Weihong Tan, and Zhikai Tan. “In Vitro Study of Colon Cancer Cell Migration Using E-Jet 3D Printed Cell Culture Platforms”. Macromol Biosci 2018; 18(11): e1800205. (IF: 5.859)
13. Li Sun, Yuan Huang, Yeying Liu, Yujie Zhao, Xiaoxiao He, Lingling Zhang, Feng Wang and Yingjie Zhang*. “Ipatasertib, a novel Akt inhibitor, induces transcription factor FoxO3a and NF-κB directly regulates PUMA-dependent apoptosis”. Cell Death & Disease 2018; 9(9): 911. (IF: 9.685)
14. Xianwang Wang, Xiaochun Peng, Xueqing Zhang, Hanyi Xu, Chengbiao Lu, Lian Liu, Jiaxing Song, Yingjie Zhang*. “The Emerging Roles of CIB1 in Cancer”. Cell Physi Biochemi 2017; 43: 1413-1424.
15. Zhikai Tan, Yikun Yang, Shurui Liao, Juchang Zhong, Yingjie Zhang*, Weihong Tan. “3D printed scaffolds for tumor targeting and controlled drug release”. J Controlled Release 2017; 259: e5-e195. (IF: 11.467)
16. Lingling Zhang, Huanan Wang, Wei Li, Juchang Zhong, Rongcheng Yu, Xinfeng Huang, Honghui Wang, Zhikai Tan, Jiangang Wang, Yingjie Zhang*. “Pazopanib, a novel multi-kinase inhibitor, shows potent antitumor activity in colon cancer through PUMA-mediated apoptosis”. Oncotarget 2017; 8(2): 3289-3303.
17. Li Sun, Defeng Wang, Xiaotian Li, Lingling Zhang, Hui Zhang, Yingjie Zhang*. “Extracellular matrix protein ITGBL1 promotes ovarian cancer cell migration and adhesion through Wnt/PCP signaling and FAK/SRC pathway”. BIOMED PHARMACOTHER 2016; 81: 145-151. (IF: 7.419)
18. Lei Wang, Ji Wang, Hua Xiong, Fengxia Wu, Tian Lan, Yingjie Zhang, Xiaolan Guo, Huanan Wang, Mohammad Saleem, Cheng Jiang, Junxuan Lu, Yibin Deng. “Co-Targeting Hexokinase 2-Mediated Warburg Effect and ULK1-Dependent Autophagy Suppresses Tumor Growth of PTEN- and TP53-Deficiency-Driven Castration-Resistant Prostate Cancer”. EBioMedicine 2016; 7: 50-61. (IF: 11.205)
19. Huanan Wang, Lei Wang, Yingjie Zhang, Ji Wang, Yibin Deng, Degui Lin. “Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth” Cancer Cell Int. 2016; 16(16): 9. (IF: 6.429)
20. Huanan Wang, Lingling Zhang, Xu Yang, Yipeng Jin, Shimin Pei, Di Zhang, Yingjie Zhang* and Degui Lin*. “PUMA Mediates the Combinational Therapy of 5-FU and NVP-BEZ235 in Colon Cancer” Oncotarget 2015; 6(16): 14385-98.
21. Lei Wang, Hua Xiong, Fengxia Wu, Yingjie Zhang, Ji Wang, Liyan Zhao, Xiaolan Guo, Li-Ju Chang, Yong Zhang, M. James You, Shahriar Koochekpour, Mohammad Saleem, Haojie Huang, Junxuan Lu and Yibin Deng. “Hexokinase 2-Mediated Warburg Effect Is Required for PTEN and p53 Deficiency-Driven Prostate Cancer Growth”. Cell Rep 2014; 8: 1-14. (IF: 9.995)
22. Jie Feng, Yingjie Zhang and Da Xing. “Low-power laser irradiation (LPLI) promotes VEGF expression and vascular endothelial cell proliferation through the activation of ERK/Sp1 pathway”. Cellular Signalling. 2012; 24: 1116-1125. (IF: 4.85)
23. Yingjie Zhang and Da Xing. “PUMA Promotes Bax Activation in a FOXO3a-dependent Manner in STS-induced Apoptosis”. J Innov Opt Health Sci 2010; 3: 31-38. (IF: 2.396)
24. Lingling Zhang, Yingjie Zhang and Da Xing. “LPLI Inhibits Apoptosis Upstream of Bax Translocation via a GSK-3β-Inactivation Mechanism”. J. Cell. Physiol. 2010; 224(1): 218-228 (Cover Story). (IF: 6.513)
25. Yingjie Zhang, Da Xing and Lei Liu. “PUMA promotes Bax translocation by both directly interacting with Bax and by competitive binding to Bcl-XL during UV-induced apoptosis”. Mol. Biol. Cell. 2009; 20: 3077-3087. (IF: 3.612)
26. Yingjie Zhang, Da Xing and Lei Liu. “The molecular imaging study of PUMA and Bcl-2 family members in UV-induced apoptosis”. Chinese Journal of Lasers 2009; 36 (10): 2609-2613.
27. Yingjie Zhang* and Qun Chen. “PUMA Promotes Bax Translocation in FOXO3a-dependent Pathway during STS-induced Apoptosis”. Proc. of SPIE. 2009; 7519: 75191A1-9.
28. Lei Liu, Yingjie Zhang and Xianwang Wang. “Using FRET Technique to Investigate The Apoptotic Mechanism Induced by Cisplatin in Living Cells”. Progress in Biochemistry and Biophysics 2009; 36 (9): 1172-1179
29. Lei Liu, Yingjie Zhang and Xianwang Wang. “Involvement of Caspase-dependent and –independent apoptotic pathways in cisplatin-induced apoptosis”. Proc. of SPIE. 2009; 7178: 71780N1-8.
30. Yingjie Zhang, Da Xing, Yinyuan Wu and Lei Liu. “PUMA promotes Bax translocation by competitive binding to Bcl-Xl during UV-induced apoptosis”. Proc. of SPIE. 2008; 6857:
獎勵與榮譽：
1. 主講課程《細胞工程》入選2019年湖南省一流課程
2. 湖南省2019年普通高校教師課堂教學競賽二等獎
3. 2003网站太阳集团2018年講課比賽一等獎
4. 2003网站太阳集团2018年本科畢業設計（論文）優秀指導教師
5. 2016年度深圳市科技項目獎先進個人
